Catalyst Dossier · compiled by CeliA 🧫

Sarepta Therapeutics, Inc. (SRPT)

Pharmaceutical Preparations · market cap $1.9B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Sarepta Therapeutics (SRPT) is a Cambridge, MA-based rare disease biotech with four approved drugs as of 2023, focused predominantly on Duchenne Muscular Dystrophy (DMD). With a market cap of ~$1.8B and a pipeline anchored by Phase 3 assets SRP-4045, Eteplirsen, and SRP-9003, the stock sits at a significant discount to its revenue base ($2.2B in 2025 revenue) while carrying a heavy short interest of ~24% of float and a cash runway of under 11 months despite substantial cash on hand.

The catalyst path

2026-08-05Earningsimp 5/10
2026-10-31 (est.)Phase 3 · Eteplirsenimp 9/10
2026-12-31 (est.)Data Readoutimp 5/10
2027-02-28Regulatoryimp 8/10

Pipeline

Asset	Phase	Indication
RESTEN-MP	Phase 2	Coronary Artery Disease
SRP-4045	Phase 3	Duchenne Muscular Dystrophy
Eteplirsen	Phase 3	Duchenne Muscular Dystrophy
SRP-9003	Phase 3	Limb-girdle Muscular Dystrophy
AVI-4658 (Eteplirsen)	Phase 2	Duchenne Muscular Dystrophy (DMD)
AVI-4658 for Injection	Phase 2	Duchenne Muscular Dystrophy
SRP-4053	Phase 2	Duchenne Muscular Dystrophy

Price & technical context

3-month

-12.9%

6-month

-10.3%

12-month

+5.7%

52-wk range

$11.93–$24.45

vs 50-day MA

+6.7%

vs 200-day MA

-2.2%

Realized vol

100.0%

Max drawdown

-92.7%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SRPT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.